Table 3 Univariate and multivariate analyses of significant biomarkers for OS in 84 bmCRPC-patients under Abiraterone-therapy

PSA decline ≥ 50 % no vs. yes

4.2 (2.3–7.6)

<0.001

PSA decline ≥ 50 % no vs. yes

2.8 (1.2–6.3)

0.016

No-Bouncing vs. ALP-Bouncing

3.1 (1.7–5.7)

<0.001

No-Bouncing vs. ALP-Bouncing

2.0 (0.7–5.7)

0.181

ALP rising after 12 w yes vs. no

4.9 (2.7–8.9)

<0.001

ALP rising after 12 w yes vs. no

1.5 (0.6–3.9)

0.412

ECOG 2 vs. 0–1

2.7 (1.4–5.0)

0.002

ECOG 2 vs. 0–1

1.4 (0.6–3.1)

0.387

PSA decline ≥ 90 % no vs. yes

3.0 (1.5–6.1)

0.003

-

-

-

LDH normalization no vs. yes

2.6 (1.3–5.0)

0.005

LDH normalization no vs. yes

1.8 (0.8–3.9)

0.143

LDH BL > UNL yes vs. no

2.1 (1.0–4.3)

0.048

LDH BL > UNL yes vs. no

1.2 (0.2–7.1)

0.826

Visceral Mets. yes vs. no

1.8 (0.9–3.3)

0.076

Visceral Mets. yes vs. no

1.0 (0.5–2.2)

0.076

AA post-CTX vs. pre-CTX

1.5 (0.8–2.7)

0.175

-

-

-

ALP BL > UNL yes vs. no

1.4 (0.8–2.5)

0.199

-

-

-

GS ≥ 8 vs. GS < 8

1.3 (0.7–2.4)

0.365

-

-

-

Lnn. Mets. yes vs. no

0.9 (0.6–1.6)

0.804

-

-

-